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Abstract
To improve the adherence to and knowledge about pharmacotherapy in outpatients and to maximize the efficacy
and minimize the adverse drug events, the first pharmacist-managed clinic (PMC) in Japan was established for
anticoagulation therapy at Nagoya University Hospital in 2000. Since then, various PMCs such as for asthma/chronic
obstructive pulmonary disease, Alzheimer’s disease, hypercholesterolemia, chronic hepatitis C, cancer chemotherapy,
palliative care, chronic kidney disease, and continuous ambulatory peritoneal dialysis have been established and
expanded to many hospitals in Japan. Accumulating evidences suggest that PMCs have some beneficial effects on
patients’ adherence to and knowledge about their pharmacotherapy as well as the clinical outcome, besides being
cost-effective. Notably, PMCs for cancer chemotherapy have been approved as a new medical service in hospitals in
2014, which is covered by the universal health coverage in Japan. In this review article, the current status of PMCs
for patient education and counseling in Japan and their impact on pharmaceutical care and management are
critically reviewed. Furthermore, future perspectives on PMCs are discussed.
Keywords: Pharmacist-managed clinic, Pharmaceutical care, Adherence, Patient education, Anticoagulation,
Asthma, COPD, Alzheimer’s disease, Cancer chemotherapy
Introduction
Pharmacists can contribute to positive outcomes of pharma-
cotherapy by educating and counseling patients to prepare
and motivate them to follow their pharmacotherapeutic
regimens and monitoring plans. Education and counseling
are most effective when conducted in a room or space that
ensures privacy and the opportunity to engage in confiden-
tial communication [American Society of Health-System
Pharmacists (ASHP) guidelines on pharmacist-conducted
patient education and counseling] [1]. Reinders and Steinke,
for instance, reported the development, operation, patient
management protocol, and teaching activities of a
pharmacist-managed anticoagulation clinic for ambulatory
patients in 1979. They concluded that this clinic gives the
pharmacist a unique opportunity to provide comprehensive
pharmaceutical services, to establish effective, long-term
professional relationships with ambulant patients and their
families, and to foster interdisciplinary health team activities
[2]. To date, various pharmacist-managed clinics (PMCs) for
chronic diseases or symptoms in different clinical settings
have been reported in the United States [3-22] and other
countries [23-28]. These include clinics undertaking educa-
tion and counseling for anticoagulation [2,23,25-27], asthma
[3], Helicobacter pylori infection [4], diabetes [7], hyperlipid-
emia [8,9], hypertension [10,11], latent tuberculosis infection
[12], pain [13,14], smoking cessation [15], and cancer
chemotherapy [21,22]. Beneficial effects of PMCs have been
repeatedly reported in terms of cost-effectiveness, patients’
adherence to and knowledge about pharmacotherapy, and
the outcome of treatment [29-34].
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shima), which was supported by a Health Labour Science
Research Grant (H10-Iyaku-068, 1998–2000) from the
Ministry of Health, Labour, and Welfare of Japan, played
an indispensable role in the introduction and development
of pharmacist-managed clinics (PMCs) for patient educa-
tion and counseling in Japan. In this 3-year program, 10
Japanese pharmacists studied abroad to see clinical phar-
macy practices in the United States, and 8 visiting clinical
pharmacists from foreign countries introduced PMCs and
other pharmacy services, as well as pharmacy education,
to Japan [35,36].
The first PMC in Japan was established for anticoagula-
tion therapy with warfarin at Nagoya University Hospital
in 2000 [37-39]. This was triggered by a request from a
medical doctor in the vascular surgery department for
hospital pharmacists to conduct patient education and
pharmaceutical counseling for those who had taken
warfarin for a long period, but for whom the prothrombin
time-international normalized ratio (PT-INR) value was
unstable and sometimes outside of the target range. A
hospital pharmacist, Dr. Keiko Yamamura, played an in-
dispensable role in establishing this PMC. Implementation
of this new clinical practice involving patient education
and counseling was first reported in the 10th Clinical
Pharmacy Symposium in Japan (Chiba, Japan, 2002). A
PMC for asthma was also started at Nagoya University
Hospital in 2001, for which a pharmacist, Dr. Masaya
Hasegawa, played a crucial role [39,40]. At the same time, a
PMC for asthma was introduced by Dr. Ritsuko Taniguchi
into pharmacy education at Okayama University School of
Pharmacy [41]. Drs. Yamamura, Hasegawa, and Taniguchi
had all studied abroad with support from the international
exchange program mentioned above [35].
At present, various PMCs are in operation at hospital
pharmacies in Japan [42-50] (Table 1). For example, we
now operate 7 PMCs at Nagoya University Hospital, such
as for anticoagulation therapy, asthma/chronic obstructive
pulmonary disease (COPD), donepezil outpatient consult-




Asthma/chronic obstructive pulmonary disease (COPD) [39-41,69-71]
Donepezil outpatient consultation service (DOCS) [39,44]
Cancer chemotherapy [45-50]
Chronic kidney disease not available
Continuous ambulatory peritoneal dialysis not available
Hypercholesterolemia [42]
Chronic hepatitis C [43]disease, molecular-targeted drugs, and continuous am-
bulatory peritoneal dialysis. Some of them are run in
collaboration with schools of pharmacy. A PMC for
DOCS is an example of such hospital pharmacist/fac-
ulty pharmacist collaboration. The DOCS provides
pharmaceutical education and counseling about the
pathophysiology of Alzheimer’s disease and drug ther-
apy with donepezil and other drugs to outpatients and
their family members [44]. We have demonstrated that
the DOCS improves understanding of the clinical fea-
tures of Alzheimer’s disease in patients and provides
pharmacological knowledge about antidementia drugs,
leading to significantly better adherence to pharmaco-
therapy with donepezil [44].
As a distinct feature of PMCs in Japan, the number of
PMCs for cancer chemotherapy has rapidly increased in
parallel with a paradigm shift of the treatment from inpa-
tients to outpatients [45-50]. Of note, PMCs for cancer
chemotherapy have been approved as a new medical
service in hospitals in 2014, and are covered by the univer-
sal coverage in Japan, if certified oncology pharmacists, in
agreement with physicians, conduct patient education and
counseling about cancer chemotherapy with the consent
of patients.
PMCs for anticoagulation therapy
Oral anticoagulation therapy with warfarin is beneficial for
the primary and secondary prevention of life-threatening
thromboembolic events. Warfarin exhibits anticoagulant
actions and prophylactic effects on thrombosis by inhibiting
the synthesis of vitamin K-dependent coagulation factors. It
is useful for a variety of conditions including venous
thromboembolism, atrial fibrillation, mechanical prosthetic
heart valves, coronary artery disease, and stroke [51,52].
There are some limitations, however, as to its safe and
effective use. A narrow therapeutic index, hemorrhagic
side effects, variations in dosage requirements, adherence,
and multiple drug-drug and drug-food interactions all
limit its clinical effectiveness or enhance its toxicity. In
particular, the risk of major bleeding on warfarin is
approximately 1-5% per year, and bleeding complications
due to anticoagulants are among the most frequent
adverse drug effects (ADEs) [53]. Accordingly, management,
education, and counseling for anticoagulation therapy in
outpatients are necessary and important for appropriate
pharmacotherapy [54].
It has been reported that all hemorrhagic and thrombo-
embolic events associated with warfarin were significantly
reduced by a PMC in the University of Florida’s Family
Practice [32]. Furthermore, by avoiding hospitalization
and emergency room visits due to thromboembolic or
hemorrhagic complications, potential cost avoidance was
estimated if the control group had been followed by the
anticoagulation monitoring service [32]. A retrospective
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tion clinic with physician management was recently re-
ported using INR stability. The study demonstrated that
the pharmacist-managed anticoagulation clinic had higher
rates of INRs determined to be therapeutic and exhibited
significantly less variability in therapeutic INR rates relative
to a physician-managed service [33].
A cross-sectional pre- to post-counseling study was
conducted at Nagoya University Hospital to assess the ef-
fects of a PMC for anticoagulation therapy on patients’
knowledge and the quality of the treatment [38]. This PMC
significantly improved the patients’ knowledge about war-
farin treatment and reduced the mean deviation from the
PT-INR target range [37,38].
The development of reliable and accurate devices to
measure PT-INR, such as Coaguchek, Pro Time Micro-
coagulation System, and Coumatrak monitor, has allowed
self-testing by patients at home. A systematic review and
meta-analysis of individual patient data showed that self-
monitoring and self-management of oral anticoagulation
are a safe option for suitable patients of all ages [55]. We
have recently started clinical research to assess the safety
and effectiveness of internet-based PMC for anticoagula-
tion therapy with warfarin in combination with self-
monitoring of PT-INR in patients who may have potential
adverse drug interactions with warfarin. For example, both
fluorouracil and miconazole are known to exhibit drug-
drug interactions with warfarin, leading to potential side ef-
fects [56,57]. Accordingly, we applied the self-management
of warfarin treatment supported by an internet-based PMC
in combination with self-monitoring of PT-INR to 2 pa-
tients receiving concomitant treatment with either FOLFIRI
chemotherapy [58] or miconazole gel [59]. By using the
time in the therapeutic range as a measure of the quality of
treatment [60], we reported that the internet-based PMC in
combination with self-monitoring of PT-INR may be safe
and effective for pharmacotherapy management of anticoa-
gulation therapy in high-risk patients with potential drug-
drug interactions [58,59].
In addition to warfarin, novel oral anticoagulants such as
Factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban,
as well as a direct thrombin inhibitor, dabigatran etexilate,
have recently become available for anticoagulation therapy
[52]. Because these new drugs also have some risks for
bleeding and other ADEs [61,62], we have included pharma-
ceutical education and counseling on novel oral anticoagu-
lants in the PMC at Nagoya University Hospital.
PMCs for asthma/COPD
Asthma and COPD are pulmonary disorders characterized
by various degrees of airflow limitation, inflammation, and
tissue remodeling. There are clear differences between
these two diseases; the former originates in childhood and
is best treated with anti-inflammatory steroids, whereasthe latter occurs in adults who smoke and is best treated
with bronchodilators and the removal of risk factors. The
most important difference between asthma and COPD is
the nature of the inflammation, which is primarily eosino-
philic and CD4-driven in asthma, and neutrophilic and
CD8-driven in COPD [63].
Asthma and COPD patients are mainly treated with in-
halation medication, but it is difficult for many patients to
use such medication correctly [64]. Thus, PMC for asthma/
COPD should include education on how to use inhalation
devices correctly. Furthermore, although exacerbations are
potentially preventable by appropriate pharmacotherapy,
patients often have difficulty following prescribed regimens.
Thus, PMC for asthma/COPD may be able to enhance
patient compliance and outcomes by engaging in pharma-
ceutical care activity such as monitoring symptoms, provid-
ing proper education on the correct handling of inhalation
devices and inhalation technique, and medication counsel-
ing, helping resolve drug-related problems, and facilitating
communication with physicians [65-68].
A large randomized controlled trial was conducted at 36
community drugstores (1113 participants) in the United
States to assess the effectiveness of a pharmaceutical care
program for patients with asthma or COPD [65]. Thirty-six
drugstores were divided into 3 clusters: Pharmaceutical
Care Program group, Peak Flow Monitoring Control group,
and Usual Care Control group. The pharmaceutical care
program provided pharmacists with recent patient-specific
clinical data (peak expiratory flow rates, [PEFRs], emer-
gency department visits, hospitalizations, and medication
compliance), training, customized patient educational ma-
terials, and resources to facilitate program implementation.
The PEFR monitoring control group received a peak flow
meter, instructions about its use, and monthly calls to elicit
PEFRs. However, PEFR data were not provided to the
pharmacist. Patients in the usual care control group
received neither peak flow meters nor instruction on their
use; during monthly telephone interviews, PEFR rates were
not elicited. The pharmaceutical care program increased
patients’ PEFRs compared with those upon usual care, but
provided little benefit compared with peak flow monitoring
alone. Pharmaceutical care increased patient satisfaction
but also increased the number of breathing-related emer-
gency department or hospital visits (care-seeking behavior).
These findings were interpreted as follows: implementa-
tion of the pharmacy program was poor, perhaps due to
limited time or lack of incentives to use the resources pro-
vided, and resulted in limited benefits in terms of clinical
endpoints [65].
On the other hand, a recent review article supported the
National Heart, Lung, and Blood Institutes of the National
Institute of Health Expert Panel Report 3 guidelines in rec-
ognizing pharmacists as accessible healthcare practitioners
who, via patient education and medication management,
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disease state [66]. Furthermore, in a randomized, con-
trolled, prospective clinical trial with a total of 133 COPD
patients, significant improvements of COPD knowledge,
medication adherence, medication beliefs, and a significant
reduction in hospital admission rate were demonstrated by
pharmaceutical care intervention delivered by clinical phar-
macists [67]. A large-scale prospective cohort study in
community pharmacies in Netherlands, in which the pri-
mary outcome was the reduction of oral high-dosage cor-
ticosteroids or antibiotics, demonstrated that community
pharmacists actively providing comprehensive pharmacy
care could improve effective treatment in asthma and
COPD patients and thereby decrease the number of pre-
scriptions for exacerbations in these patients [68].
A cross-sectional pre- to post-education/counseling study
with 116 patients, who attended the PMC for asthma at
Nagoya University Hospital, was conducted to assess the ef-
fects of the PMC on patients’ knowledge about the patho-
physiology and drug treatment for asthma, inhalation skills,
and clinical outcome [40]. The PMC significantly improved
patients’ knowledge about the disease and its drug treat-
ment. Furthermore, repeated counseling in the PMC im-
proved PEFR and maintained it at a high level for over
2 years [40]. Subsequent studies demonstrated that pharma-
ceutical education and counseling in the PMC for asthma
were effective in enhancing patients’ knowledge and adher-
ence and increasing the PEFR of patients with any disease
severity from mild to severe [69,70]. Significant positive
correlations of medication adherence with inhalation tech-
nique and insights into the disease and medication were
observed, but not with the state of disease control. It is
suggested that patients who use an incorrect inhalation tech-
nique or have insufficient knowledge about the medication
and pathophysiology have poor medication adherence [71].
PMCs for cancer chemotherapy
Adherence to oral chemotherapy regimens maximizes their
effectiveness and minimizes any potential toxicity. It is sug-
gested that patients with life-threatening conditions such
as cancer would be highly motivated to follow their treat-
ment regimens [72], but the available evidence suggests
that a substantial population of patients, for example, teen-
age and young adult patients with cancer, have difficulty
adhering to treatment regimens. Factors that affect treat-
ment adherence in young patients with cancer include pa-
tient emotional functioning (depression and self-esteem),
patient health beliefs (perceived illness severity and vulner-
ability), and family environment [73]. A recent study in
postoperative breast cancer patients before pharmacist
counseling for adjuvant systemic therapy at Nagumo Clinic
in Tokyo revealed that fatigue, emotional functioning, sys-
temic therapy side effects, future perspectives, and appetite
loss are determinants affecting the quality of life. Takingthese factors into consideration will aid pharmacist educa-
tion and counseling [74]. Treatment-related factors that
may influence medication adherence include complexity of
the regimen, the cost of therapy, the possibility of side ef-
fects, and the delay in treatment benefits. Meanwhile, pa-
tients may not have an adequate support system or an
understanding of the need for medication, and providers
may not fully succeed in communicating the importance of
adherence and the types of side effects that may occur [75].
Many studies have repeatedly and consistently reported
the beneficial role of clinical pharmacists and PMCs for
cancer chemotherapy in oncology settings in the United
States and other countries [21,22,76-82]. For instance, a
cross-sectional survey revealed that patients are interested
in visiting a pharmacist regularly during chemotherapy
treatment and may be willing to pay for a pharmacy coun-
seling service [21]. A retrospective analysis of clinical in-
terventions, cost-savings, and feedback from patients and
colleagues confirmed the beneficial nature of services pro-
vided by clinical oncology pharmacists in an outpatient
oncology center [22]. In a recent retrospective observa-
tional cohort study assessing the effectiveness of an oral
chemotherapy management (OCM) clinic providing com-
prehensive medication therapy management (MTM) ser-
vices, including education on various oral chemotherapy
agents, concurrent medications, and symptom management
as well as insurance assistance, it was indicated that this
clinic is effective in delivering early interventions, resulting
in decreased rates of adverse effects, nonadherence, drug
interactions, and medication errors over time [78].
Chemotherapy-induced nausea and vomiting (CINV)
represent significant side effects in cancer patients. Poorly
controlled CINV can lead to a decrease in the quality of life
of patients, and to a change in the chemotherapy regimen.
A 4-month longitudinal prospective intervention study was
conducted to analyze the effects of pharmaceutical care
(reviewing the antiemetic protocol and giving some recom-
mendations to patients) on the incidence of delayed CINV
in adult cancer outpatients. It was concluded that pharma-
ceutical intervention by pharmacists reduces the incidence
of delayed CINV and improves medication adherence
[79]. Another report described a collaborative practice
agreement between pharmacists and physicians as one
approach to managing chemotherapy-induced anemia
in hematology-oncology patients in an anemia clinic.
The pharmacist's role was justified in this clinic model
through increased adherence to evidence-based prac-
tice guidelines and decreased costs associated with
erythropoietin-stimulating agent therapy [83]. Alterna-
tively, it was indicated that health-system pharmacists
played an important role in screening patients with a
history of breast or prostate cancer for bone loss or
osteoporosis, making drug therapy recommendations
to address the problem, and counseling patients on
Table 2 The proposal to improve the quality of PMCs in
Japan
1. To develop guidelines for PMCs
2. To provide evidence that patient education and counseling in PMCs
are valuable in the following viewpoints:
a. adherence to pharmacotherapy
b. knowledge about pharmacotherapy
c. clinical outcome
d. cost-effectiveness
3. Outreach activity for PMCs
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of drug therapies to improve bone health [84].
In Japan, hospital pharmacists mix anticancer agents for
intravenous cancer chemotherapy for both outpatients and
inpatients and check the regimens. Furthermore, clinical
pharmacists are expected to participate actively in cancer
chemotherapy with pharmaceutical knowledge and skills to
enhance patient understanding and adherence to the regi-
mens and to secure the safety of treatment. Accordingly,
the number of PMCs for cancer chemotherapy has rapidly
increased in parallel with a paradigm shift of treatment
from an inpatient to an outpatient basis [45-50].
The initial PMC for cancer chemotherapy was focused
on patients taking TS-1 at Kyoto University Hospital, and
participated in safe and effective chemotherapy for outpa-
tients [45]. The usefulness of PMC for XELOX (capecita-
bine plus oxaliplatin) therapy in colorectal cancer patients
was evaluated at the Cancer Institute Hospital of the Japanese
Foundation for Cancer Research, in which pharmacists
interviewed patients about their medication compliance,
adverse effects, and supportive care, in advance of a physi-
cian’s assessments [48]. The endpoints included the num-
ber and content of inquiries about XELOX and the rate of
adoption of suggestions by pharmacists for supportive
care. The number of inquiries concerning XELOX was
significantly fewer in the PMC group with pharmaceutical
interventions (14/260 patients, 5.3%) than in the control
group without consultation in the PMC (43/256 patients,
16.8%) [48]. A recent assessment of a PMC for cancer
chemotherapy at the International University of Health
and Welfare Mita Hospital indicated that the respective
degrees of understanding of drugs, treatment schedule,
and the side effects and their prevention were significantly
improved by consultation in the PMC compared with
those without PMC consultation. In this study, a majority
of patients (44/50, 88%) who had had some anxiety about
chemotherapy reported that their anxiety levels were
reduced by the counseling in the PMC [49]. The outcome
analysis of pharmaceutical care in outpatients who had
received cancer chemotherapy at Shiga University of
Medical Science Hospital indicated that the rate of
amelioration of symptoms associated with chemother-
apy was significantly higher (94/145 cases, 65%) when a
pharmacist’s suggestions about the prescription were
adopted by the physician than the rate when the sug-
gestions were not adopted (6/17 cases, 35%) [50]. These
results support the clinical significance of PMCs for
cancer chemotherapy, while the cost-effectiveness of
this clinical practice by pharmacists should be demon-
strated in future studies.
Future perspectives
PMCs for patient education and counseling in Japan are
now expanding from anticoagulation therapy to cancerchemotherapy at hospital pharmacies. However, the con-
tents of PMC as well as the clinical effects may vary
depending upon the hospitals where the service is pro-
vided, the diseases/symptoms and pharmacotherapy that
are targeted, and the knowledge and skills of individual
pharmacists who participate in PMCs. The effects of
PMCs on cost-effectiveness, patients’ adherence to and
knowledge about pharmacotherapy, and clinical outcome
have not yet been completely clarified in Japan. Further-
more, patient education and counseling at community
pharmacies in the country have been limited, and there
are few published reports about the implementation of
PMCs at community pharmacies and their clinical impact.
Last but not least, there has been almost no outreach
activity for PMCs offered in Japan.
In spite of this background, PMCs for cancer chemother-
apy have been approved as a new medical service in hospi-
tals, and are covered by the universal health coverage in
Japan. One might interpret this as a result of our continuous
efforts; hospital pharmacists have provided pharmaceutical
care and management for inpatients during the last 20 years,
so their roles in pharmacotherapy management and patient
education and counseling are now well recognized by
medical staff and health insurance providers in Japan.
To maintain or even increase the reliability of both
hospital pharmacists and community pharmacists as pro-
fessionals for pharmaceutical care and management, we
need to understand the current status and problems of
PMCs mentioned above, and then refine the system
(Table 2). There is an urgent need to develop guidelines
for PMCs, which could be universally adapted in various
clinical settings from cancer chemotherapy at hospital phar-
macies to anticoagulation therapy and asthma/COPD treat-
ment at community pharmacies. Such PMC guidelines
should include the purpose, background, required know-
ledge and skills of pharmacists, the environment, the phar-
macists’ roles, the steps in the patient education and
counseling process, content, and documentation [1]. It is de-
sirable for the Japanese Society of Hospital Pharmacists
(JSHP) to take a leadership role in developing such guide-
lines in collaboration with the Japan Pharmaceutical Associ-
ation. In PMCs operated in accordance with such guidelines,
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evidence that patient education and counseling by pharma-
cists have beneficial effects on patients’ adherence to and
knowledge about their pharmacotherapy as well as the clin-
ical outcome, besides being cost-effective. In addition, we
need to undertake deep consideration of the outreach activ-
ity for PMCs, through which the roles of hospital pharma-
cists in pharmacotherapy management in PMCs, such as for
cancer chemotherapy, can be further appreciated by society.
Conclusions
Since the first PMC in Japan was established for anticoagu-
lation therapy with warfarin at Nagoya University Hospital
in 2000, various PMCs have been expanded and imple-
mented at hospital pharmacies in the country. As a result,
PMCs for cancer chemotherapy have been approved as a
new medical service in hospitals in 2014, and are covered
by the universal health coverage in Japan. Although benefi-
cial effects of PMCs on cost-effectiveness, patients’ adher-
ence to and knowledge about pharmacotherapy, and the
outcome of treatment have been repeatedly reported in the
United States, the evidence is limited in Japan. There is an
urgent need to develop guidelines on PMCs, which could
be universally adapted in various clinical settings. We
should evaluate our clinical practice and provide evidence
that patient education and counseling by pharmacists are
clinically valuable. Furthermore, outreach activity for PMCs
should be offered, through which the roles of hospital
pharmacists in pharmacotherapy management in PMC will
be further appreciated by society.
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